{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-026205","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.894610+00:00","generated_at":"2026-05-17T14:24:15.249265+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DiaMedica Therapeutics Reports Q2 2025 Financial Results and Positive Phase 2 Interim Data for DM199 in Preeclampsia","bullets":["Phase 2 Part 1a interim data (n=28) showed statistically significant reductions in blood pressure and uterine artery pulsatility index with no placental transfer of DM199.","Raised $30.1 million in July 2025 private placement, extending proforma cash to ~$60M and funding operations into H2 2027.","ReMEDy2 Phase 2/3 trial for acute ischemic stroke enrollment progressing; interim analysis on first 200 patients expected Q2 2026.","Appointed Julie Krop, MD, as Chief Medical Officer in August 2025; added to Russell 2000 and 3000 Indexes in June 2025.","Net loss for Q2 2025 was $7.7 million, up from $5.1 million in Q2 2024; R&D expenses increased to $5.8 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-026205","json":"https://secwatch.observer/filing/0001437749-25-026205.json","markdown":"https://secwatch.observer/filing/0001437749-25-026205.md","text":"https://secwatch.observer/filing/0001437749-25-026205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925026205/0001437749-25-026205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925026205/dmtp20250811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T14:24:15.249265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}